-
Technology
-
Industry
-
Solutions
-
- ASSET MANAGEMENT
- AUGMENTED & VIRTUAL REALITY
- COLLABORATION
- CONVERSATIONAL
- CUSTOMER EXPERIENCE MANAGEMENT
- CUSTOMER RELATIONSHIP MANAGEMENT
- CYBER SECURITY
- DATA CENTER
- DIGITAL CUSTOMER EXPERIENCE
- DOCUMENT MANAGEMENT
- EHS SOFTWARE
- ELECTRONIC DATA INTERCHANGE
- ENTERPRISE DATA MANAGEMENT
- ENTERPRISE DATA QUALITY MONITORING
- ENTERPRISE RESOURCE PLANNING
- ENTERPRISE RISK MANAGEMENT
- ENTERPRISE-GRADE WEB DATA SOLUTIONS
- FACILITY MANAGEMENT
- FIELD SERVICE
- GAMIFICATION
- IDENTITY AND ACCESS MANAGEMENT
- INFRASTRUCTURE
- IT SERVICE MANAGEMENT
- MANAGED IT SERVICES
- PAYMENT AND CARD
- PROJECT MANAGEMENT
- SOFTWARE TESTING
- STORAGE
- VIDEO SOLUTIONS
- WORKFLOW
-
-
Platforms
-
Functions
- Leadership Perspectives
- Innovation Insights
- Research
- Magazines
- News
- CXO Awards
Ferry Tamtoro, Co-Founder and CTOAddressing this challenge with its leading, SaaS-based platform for biopharma and medtech’s regulated digital health solutions is California based BrightInsight. The company’s compliant platform leverages innovative software and services to capture, transmit, and analyze data from CE-marked and FDA-regulated apps, algorithms, medical devices, combination products, companion diagnostics, and Software as a Medical Device (SaMD) to help its clients scale their regulated digital health products across regions. To eliminate complexity with respect to updating the feature-set of a digital health solution, BrightInsight is built with a microservices-based architecture, enabling rapid iterations of functionalities while maintaining compliance to a continuously changing regulatory landscape. “Our platform monitors the latest developments in the evolving healthcare compliance arena and assists clients in remaining in lockstep with them to accelerate time-to-market and ultimately drive better patient outcomes,” says Ferry Tamtoro, co-founder and CTO at BrightInsight.
Speed is paramount, and building compliant digital health products from scratch is complicated and timeconsuming. BrightInsight helps clients cut down their solution development efforts by 70 percent and accelerate goto- market with its configurable software’s Accelerator Modules on the BrightInsight® Platform. Biopharma Commercial teams use BrightInsight’s Accelerator Modules to speed the launch of digital health solutions for everything from patient diagnosis and selection to dose calculation and disease management. Clinical development teams use the robust capabilities of our software modules to quickly stand up clinical trials of digital health products. “By cutting down the time and efforts for app development, our pre-built technology accelerators allow our clients to focus on more critical aspects of their digital health solution such as clinical benefits,” explains Tamtoro.
Further discussing the core competencies of the BrightInsight Platform, Tamtoro mentions his company’s collaboration with a global pharma company, AstraZeneca. In this instance, AstraZeneca leveraged BrightInsight to monitor and maintain the compliance requirements of both the consumer-facing and clinical portals of their AMAZE Disease Management Platform.
BrightInsight took AstraZeneca’s AMAZE Disease Management Platform from project kick off to commercialization in less than a year. In a similar case, leading pharma company Roche/Genentech also approached BrightInsight during the development of their dosing calculator for treating Haemophilia A, a rare disorder that affects 400,000 people worldwide. BrightInsight helped Roche/Genentech build its regulated Software as a Medical Device (SaMD) dosing calculator in less than 6 months. “In both cases BrightInsight ensured that the building blocks of our clients’ digital health solution were compliant, thereby future-proofing their delivery and impact on patient health,” adds Tamtoro.
Our platform monitors the latest developments in the evolving healthcare compliance arena and assists clients in remaining in lockstep with them to accelerate go-to-market times and reduce risk
At the heart of BrightInsight’s success is its ability to boost go-to-market times for digital health solutions across a plethora of therapy areas and use cases, including patient diagnosis and selection to dose calculation, adherence and disease management. At the same time, the company’s proven track record, robust Quality Management System that’s ISO 13485 certified, and comprehensive list of certifications including MDSAP, HDS, ISO 62304:2015, ISO 27001:2013, HIPAA, GDPR, and more, has also helped to establish its leadership position in the digital health market. Tamtoro explained that BrightInsight regularly undergoes customer and third-party audits to support recertifications and verification of procedures, ensuring that they are always ready to support their clients’ regulated digital health products in a compliant manner.
BrightInsight is focused on its vision of transforming patient outcomes globally by bringing the power of digital technology to healthcare. Looking ahead, BrightInsight continues to develop additional Accelerator Modules to support its biopharma clients in Oncology and Autoimmune disease use cases, two indications that are seeing increased need globally. From a geographical standpoint, BrightInsight plans to strengthen its footprint in the U.S. while expanding operations into additional territories where its clients are launching products, including Canada, Australia, Japan, and more. To conclude, Tamtoro reiterates the roadmap of his company, “We will continue to incorporate emerging technologies into the BrightInsight Platform to accelerate time to market for our customer’s game changing digital health solutions that aim to improve patient outcomes.”
BrightInsight to Showcase Key Updates to its BrightInsight Platform and Disease Management Solution at HLTH 2023
Monday, October 30, 2023
SAN JOSE, Calif. and LAS VEGAS,-- BrightInsight, Inc., provider of the leading global platform for biopharma and medtech digital health solutions, announced today that it will showcase the latest technical enhancements to the BrightInsight® Platform and Disease Management Solution at the HLTH conference taking place October 8–11, 2023, in Las Vegas. Since initially launching the BrightInsight Platform in 2018, the company has invested over $100M in its underlying infrastructure – which allows it to deliver industry-leading scalability, functionality, configurability, speed, compliance and global availability.
“We fundamentally believe that digital companion apps can enhance the patient journey by providing digital interventions that support patients — which may include securing prior-authorization and co-pay support to fill a prescription, step-by-step tutorials for self-injecting a medication at home, access to clinician support or tracking medications and symptoms over time,” said Kal Patel, M.D., CEO and Co-founder of BrightInsight. “Unlike the many point solutions available in the market today, our compliant BrightInsight Platform and Disease Management Solution allow biopharma companies to develop digital solutions that can scale across disease states, geographies and brands.”
“Forward-thinking biopharma leaders are developing digital products to enhance their therapies, which means either further extending their already complex internal digital organizations or partnering to expand their capabilities,” said Diana McKenzie, former Chief Information Officer for Workday and Amgen. “BrightInsight allows life sciences companies to deploy differentiating customer-facing solutions faster, with configurable, out-of-the-box features. Moreover, as the global regulatory and cybersecurity landscape becomes increasingly dynamic and complex, BrightInsight provides a globally compliant and secure infrastructure and data platform as a service, allowing tech leaders within biopharma to focus their scarce resources at the application layer where they have the greatest likelihood of benefitting patient outcomes.”
The BrightInsight Platform now includes new mobile and data analytics capabilities, which enable our biopharma customers to rapidly build, configure, localize and optimize patient companion apps at scale, in a more cost-effective manner. The Platform can now support NFC and Bluetooth connectivity for medical device integrations across multiple device types, such as blood pressure, blood glucose, heart rate, weight and temperature monitors. Patient apps built on the BrightInsight Platform can also integrate seamlessly with Apple Health and Google Fit, as well as map and weather apps, and are interoperable through FHIR standards with Electronic Health Records (EHR) and Laboratory Information Systems (LIS). BrightInsight’s out-of-the-box data dashboards enable biopharma companies to export and analyze app utilization and engagement for ongoing app optimization, in a way that meets stringent privacy requirements.
Following the 2022 launch of its Disease Management Solution, a configurable suite of digital applications built to engage patients and providers with the aim of improving outcomes, BrightInsight has expanded its capabilities and now offers additional features that support its biopharma customers’ core use cases – from patient diagnosis, to treatment selection, to patient support program engagement and more.
New Disease Management Solution features and benefits include:
• Secure algorithm hosting and maintenance to support diagnosis and treatment selection
• Patient Support Program (PSP) integrations, including secure document sharing and prior authorization tracking
• Comprehensive and customizable multimedia educational materials
• Self-Injection/infusion management including video guides and dose tracking
• Access to nurse support with a single tap of an app, appointment tracking and physician-ordered surveys to track adherence and quality of life
• Patient journal and reports that can be easily shared with care teams
• Alerts about environmental triggers that might cause increased symptoms or flare-ups
BrightInsight will be showcasing its Platform and Disease Management Solution at Booth #2246 during the HLTH conference, taking place October 8–11 in Las Vegas.
BrightInsight, Google Cloud to Enhance Patient Experience with Generative AI
Wednesday, May 15, 2024
What You Should Know:
– BrightInsight, Inc., a provider of compliant digital health solutions, today announced its collaboration with Google Cloud to leverage cutting-edge generative AI (gen AI) technology.
– The enhanced partnership aims to optimize BrightInsight’s research and development efforts and significantly enhance its Disease Management Solution for both patients and healthcare providers.
Addressing Challenges in the Patient Journey
Across various therapeutic areas, patients often face hurdles throughout their treatment journey. These challenges include navigating access and financial barriers, transitioning between treatment options, managing complex treatment schedules, and tracking symptoms and treatment effectiveness.
Improving Patient Education and Support with AI
BrightInsight is tackling these challenges head-on by integrating Google Cloud’s Gemini and MedLM gen AI models within its Disease Management Solution. This integration offers several key benefits:
• AI-powered Chatbot: A chatbot powered by Gemini provides patients with improved access to approved educational content. Patients can receive immediate answers to their questions by leveraging a vast library of clinically validated information, eliminating the need to search through multiple documents.
• Enhanced Patient Support: The chatbot also serves as a first-line support system, offering quick and specific answers to patient inquiries regarding app usage.
Optimizing BrightInsight’s Internal Operations
BrightInsight is also utilizing Gemini Code Assist to streamline its internal R&D processes in three ways:
• Developing and Operating Google Cloud Components: Gemini Code Assist helps BrightInsight’s development team work more efficiently when building and managing Google Cloud components.
• Improved Troubleshooting: The technology assists in troubleshooting issues more effectively, saving valuable time and resources.
• Enhanced Analytics and Insights: By leveraging gen AI, BrightInsight can generate more insightful data analytics for its customers.
Leveraging MedLM for Improved Patient Data Management
Furthermore, BrightInsight is utilizing MedLM to summarize, analyze, and make patient data from companion apps more usable for clinicians. This allows for more impactful and data-driven conversations between patients and providers. For example, healthcare professionals can quickly identify missed medication doses or abnormal readings, enabling them to have focused discussions with their patients.
Prioritizing Security and Compliance
As BrightInsight advances its gen AI-based solutions, the company remains steadfastly committed to responsible implementation. Their platform and Disease Management Solution adhere to the highest security, privacy, and compliance standards, achieving certifications against global regulations. The integration of AI will follow the same rigorous approach, ensuring patient data protection.
“We have invested a lot in building best-in-class technology and hiring top engineering talent,” said Ashish Agrawal, chief technology officer, BrightInsight. “Partnering with Google Cloud and leveraging its AI technologies will enable BrightInsight to supercharge its solutions to achieve our vision of transforming patient outcomes through digital technologies.”
Company
BrightInsight
Management
Ferry Tamtoro, Co-Founder and CTO
Description
As the leading global platform for biopharma and medtech regulated digital health solutions, BrightInsight accelerates time to market and takes the hard work out of building, scaling, and maintaining compliant digital health solutions that improve patient outcomes. The company’s compliant platform leverages innovative software and services to capture, transmit, and analyze data from CE-marked and FDA-regulated apps, algorithms, medical devices, combination products, companion diagnostics, and Software as a Medical Device (SaMD) to help its clients scale their regulated digital health products across regions. BrightInsight is built with a microservices-based architecture, enabling rapid iterations of functionalities while maintaining compliance to a continuously changing regulatory landscape
